BACKGROUND/AIMS: The formation of advanced glycation end products (AGEs) is accelerated in patients with diabetic nephropathy. The aim of this study was to ascertain if the urinary excretion of proteins modified by advanced glycation can be used as biomarkers for albuminuria in individuals with type 1 or type 2 diabetes. METHODS: Community-based patients with type 1 (n = 68) or type 2 diabetes (n = 216) attending a diabetes clinic of a tertiary referral hospital were classified as having normoalbuminuria (Normo, albumin excretion rate (AER) <20 μg/min), microalbuminuria (Micro, AER 20-200 μg/min) or macroalbuminuria (Macro, AER ≥200 μg/min). Serum and urine AGE-modified proteins were measured. RESULTS: In patients with both type 1 diabetes and type 2 diabetes, there was a clear association between the degree of albuminuria and urinary AGE-modified proteins (p < 0.0001). Exclusive to patients with type 1 diabetes, urinary excretion of the AGE carboxymethyllysine correlated with AER, whereas patients with type 2 diabetes and macroalbuminuria had an increase in urinary methylglyoxal, an AGE intermediate. These changes were independent of isotopic glomerular filtration rate levels. Serum concentrations of AGEs or soluble receptor for AGEs were not consistently associated with albuminuria in either type 1 or type 2 diabetes. CONCLUSIONS: Urinary excretion of proteins modified by AGEs may be useful biomarkers of albuminuria in individuals with type 1 and type 2 diabetes, warranting prospective investigation in larger diabetic cohorts.
BACKGROUND/AIMS: The formation of advanced glycation end products (AGEs) is accelerated in patients with diabetic nephropathy. The aim of this study was to ascertain if the urinary excretion of proteins modified by advanced glycation can be used as biomarkers for albuminuria in individuals with type 1 or type 2 diabetes. METHODS: Community-based patients with type 1 (n = 68) or type 2 diabetes (n = 216) attending a diabetes clinic of a tertiary referral hospital were classified as having normoalbuminuria (Normo, albumin excretion rate (AER) <20 μg/min), microalbuminuria (Micro, AER 20-200 μg/min) or macroalbuminuria (Macro, AER ≥200 μg/min). Serum and urine AGE-modified proteins were measured. RESULTS: In patients with both type 1 diabetes and type 2 diabetes, there was a clear association between the degree of albuminuria and urinary AGE-modified proteins (p < 0.0001). Exclusive to patients with type 1 diabetes, urinary excretion of the AGE carboxymethyllysine correlated with AER, whereas patients with type 2 diabetes and macroalbuminuria had an increase in urinary methylglyoxal, an AGE intermediate. These changes were independent of isotopic glomerular filtration rate levels. Serum concentrations of AGEs or soluble receptor for AGEs were not consistently associated with albuminuria in either type 1 or type 2 diabetes. CONCLUSIONS: Urinary excretion of proteins modified by AGEs may be useful biomarkers of albuminuria in individuals with type 1 and type 2 diabetes, warranting prospective investigation in larger diabetic cohorts.
Authors: Thorsten P Degenhardt; Nathan L Alderson; David D Arrington; Robert J Beattie; John M Basgen; Michael W Steffes; Suzanne R Thorpe; John W Baynes Journal: Kidney Int Date: 2002-03 Impact factor: 10.612
Authors: M P Wautier; P Massin; P J Guillausseau; M Huijberts; B Levy; E Boulanger; M Laloi-Michelin; J L Wautier Journal: Diabetes Metab Date: 2003-02 Impact factor: 6.041
Authors: J M Forbes; T Soulis; V Thallas; S Panagiotopoulos; D M Long; S Vasan; D Wagle; G Jerums; M E Cooper Journal: Diabetologia Date: 2001-01 Impact factor: 10.122
Authors: Michael Morcos; Ahmed A R Sayed; Angelika Bierhaus; Benito Yard; Rüdiger Waldherr; Wolfgang Merz; Ingrid Kloeting; Erwin Schleicher; Stefani Mentz; Randa F Abd el Baki; Hans Tritschler; Michael Kasper; Vedat Schwenger; Andreas Hamann; Klaus A Dugi; Anne-Marie Schmidt; David Stern; Reinhard Ziegler; Hans U Haering; Martin Andrassy; Fokko van der Woude; Peter P Nawroth Journal: Diabetes Date: 2002-12 Impact factor: 9.461
Authors: Mona Sedeek; Augusto C Montezano; Richard L Hebert; Stephen P Gray; Elyse Di Marco; Jay C Jha; Mark E Cooper; Karin Jandeleit-Dahm; Ernesto L Schiffrin; Jennifer L Wilkinson-Berka; Rhian M Touyz Journal: J Cardiovasc Transl Res Date: 2012-06-19 Impact factor: 4.132
Authors: Erin L Tomaszewski; Trevor J Orchard; Marquis S Hawkins; Rebecca B N Conway; Jeanine M Buchanich; John Maynard; Thomas Songer; Tina Costacou Journal: J Diabetes Sci Technol Date: 2021-05-15
Authors: Aowen Zhuang; Felicia Y T Yap; Danielle J Borg; Domenica McCarthy; Amelia Fotheringham; Sherman Leung; Sally A Penfold; Karly C Sourris; Melinda T Coughlan; Benjamin L Schulz; Josephine M Forbes Journal: Endocrinol Diabetes Metab Date: 2021-06-22